Laboratory of Precision and Nanomedicine develops smart cancer therapeutics with increased potency and decreased side effects.
Our mission is to change the perception of cancer as being a largely incurable disease. We use in vivo peptide phage display screens to identify homing peptides that bind to specific targets in the vasculature. Corresponding synthetic peptides are explored for targeting drugs, biologicals, and nanoparticles into tumors to increase their therapeutic index. We focus on development of novel diagnostic tests and therapeutics for the early detection and precision treatment of solid tumors (glioblastoma, and breast, prostate ovarian, prostate, and colorectal carcinoma). Our lab is also at the forefront of development of next generation peptidic shuttles capable of efficient and high capacity payload delivery across the blood brain barrier.
Prof. Teesalu delivers a COST Action CA17140 Seminar - "Development of homing peptides for precision guided delivery of nanoparticles"
Written on Wednesday, 22 June 2022 12:09Prof. Teesalu delivered a seminar "Development of homing peptides for precision guided delivery of nanoparticles" in the framework of the 7th Science and the Action…
New nanosystem aimed at tumor-promoting macrophages reported in Cancer Research Communications (AACR)
Written on Wednesday, 22 June 2022 12:02In collaboration with the lab of Dr. Maria J. Vicent at the Principe Felipe Research Center in Valencia, Spain, we report development of a new…
CendR-driven cellular entrance of SARS-CoV-2 virus further decoded in a collaborative study
Written on Wednesday, 22 June 2022 11:52Our recent publication in the journal Proceedings of the National Academy of Sciences (PNAS) explains how the SARS-CoV-2 coronavirus can hijack an intracellular pathway to…
Targeted Delivery of Epidermal Growth Factor to the Human Placenta to Treat Fetal Growth Restriction.
Written on Friday, 03 December 2021 15:38Renshall LJ, Beards F, Evangelinos A, Greenwood SL, Brownbill P, Stevens A, Sibley CP, Aplin JD, Johnstone ED, Teesalu T, Harris LK. Pharmaceutics. 2021 Oct…
A widespread viral entry mechanism: The C-end Rule motif-neuropilin receptor interaction.
Written on Friday, 03 December 2021 15:37Balistreri G, Yamauchi Y, Teesalu T. Proc Natl Acad Sci U S A. 2021 Nov 16;118(49):e2112457118. doi: 10.1073/pnas.2112457118. PMID: 34772761 Abstract Many phylogenetically distant animal…
OctoberPeptide targeted polymersomes bind to M2 human macrophagesPolymersomes targeted with an M2 macrophage binding peptide (green) identified in our lab using phage display bind to and are taken up by M2s (red) originated from human primary monocytes.…
SeptemberPolymersomes targeted with an M2 macrophage binding peptide in a mouse model of triple negative breast cancerPolymersomes targeted with an M2 macrophage binding peptide (green) identified in our lab using phage display home to M2 TAMs (red) after intravenous administration in a mouse model of triple…
JanuaryHigh infiltration of CD206+ cells in human breast tumorsImmunohistochemical staining of human CD206 (brown) with nuclear counterstain (Hematoxilin, in dark blue). Authors: Anni Lepland and Pablo Scodeller.